Home > Insider Trading > Acorda Therapeutics Inc.

Acorda Therapeutics Inc. (ACOR)

Market is closed

Get Email Alerts

Profile
Hedge Fund Holdings
Insider Purchases
Insider Sales
Institutional Holdings
13 D/G Filings
News

Get Email Alerts

News

First
<< Previous
21 - 30
Next >>

13D Filing: Scopia Capital and Acorda Therapeutics Inc (ACOR)

previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), Rule 13d-1(f) or Rule 13d-1(g), check...

Keep Reading →

September 11th, 2017 - Hedge Funds

13D Filing: Scopia Capital and Acorda Therapeutics Inc (ACOR)

The remainder of this cover page shall be filled out for a reporting persons initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information...

Keep Reading →

August 8th, 2017 - Hedge Funds

13G Filing: Partner Fund Management and Acorda Therapeutics Inc (ACOR)

This Schedule 13G is being jointly filed by Partner Fund Management, L.P. (“PFM”), Partner Fund Management GP, LLC (“PFM-GP”), Partner Investment Management, L.P.

Keep Reading →

July 10th, 2017 - Hedge Funds

Here's What Is Happening In Financial Markets Today?

“Wall Street stocks on Monday were aiming to start the second quarter with tepid gains.

Keep Reading →

April 3rd, 2017 - Commodities Gold Market Movers News Tech

What Is Going On In The Financial Markets Today?

“U.S. stocks were slightly lower on Friday, dragged down by technology stocks as investors locked in gains of what is likely to be Wall Street's strongest first-quarter performance in four years.

Keep Reading →

March 31st, 2017 - Commodities Gold Market Movers News Tech

Generic Competitors A Looming Threat For Acorda Therapeutics Inc (ACOR)

In order to ensure an extension of Ampyra’s protection to 2026, Acorda Therapeutics Inc (NASDAQ:ACOR) must fight off competition from competitors such as Roxane, Teva Pharmaceutical Industries Ltd (...

Keep Reading →

February 16th, 2017 - News Stock Analysis

Can Acorda Therapeutics Inc (ACOR) Give Eli Lilly And Co (LLY) A Run For Its Money In Migraine Drug Market?

Acorda Therapeutics Inc (NASDAQ:ACOR) inhaled migraine candidate CVT-427 is seen by Janney analyst Ken Trbovich as likely to give Eli Lilly and Co (NYSE:LLY) severe competition in the migraine treatment...

Keep Reading →

January 24th, 2017 - News Stock Analysis

Acorda Therapeutics Inc (ACOR) Continues To Fall From Favor With Top Investors

Hedge funds run by legendary names like Nelson Peltz and David Tepper make billions of dollars a year for themselves and their super-rich accredited investors (you’ve got to have a minimum of $1 million...

Keep Reading →

November 28th, 2016 - Hedge Funds News